🇺🇸 FDA
Patent

US 11193128

Compositions for modulating expression of C9ORF72 antisense transcript

granted A61PA61P21/00A61P25/28

Quick answer

US patent 11193128 (Compositions for modulating expression of C9ORF72 antisense transcript) held by Ionis Pharmaceuticals, Inc. expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
44
CPC classes
A61P, A61P21/00, A61P25/28